Clinical Trial Update: Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial of GST-HG171/Ritonavir versus placebo in patients with COVID-19 pneumonia has completed recruitment and status is listed as completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• GST-HG171/Ritonavir

Snippet

Sponsor: Fujian Akeylink Biotechnology Co., Ltd. | Conditions: COVID-19 Pneumonia | Phase 2, Phase 3 | Status: COMPLETED